BIOFRONTERA AG NA O.N. news, videos and press releases
For more news please use our advanced search feature.
BIOFRONTERA AG NA O.N. - More news...
BIOFRONTERA AG NA O.N. - More news...
- DGAP-News: Biofrontera AG: Biofrontera Reports Full Year 2019 Financial Results
- DGAP-Adhoc: Biofrontera AG: Biofrontera AG enters into exclusive license agreement with Maruho Co., Ltd.
- DGAP-News: Biofrontera AG: Biofrontera reports preliminary unaudited sales revenue for the first three months of 2020
- DGAP-Adhoc: Biofrontera AG: Biofrontera AG to propose resolution for ordinary capital increase to the Annual General Meeting
- DGAP-News: Biofrontera AG:
- DGAP-Adhoc: Biofrontera AG: Biofrontera AG withdraws subscription offers for mandatory convertible bonds
- DGAP-News: Biofrontera AG: Biofrontera implements comprehensive measures to reduce costs during COVID-19 pandemic
- DGAP-Adhoc: Biofrontera AG: Biofrontera AG signs non-binding term sheet for licensing agreement for Ameluz(R) in Poland with medac GmbH Sp. z o.o.
- DGAP-Adhoc: Biofrontera AG: Biofrontera AG extends subscription period for mandatory convertible bonds
- DGAP-News: Biofrontera AG: European Commission approves use of Ameluz(R) for the treatment of actinic keratosis on extremities and trunk/neck
- DGAP-Adhoc: Biofrontera AG: Biofrontera entered into binding term sheet with Maruho Co., Ltd.
- DGAP-Adhoc: Biofrontera AG: Biofrontera AG resolves to issue qualified subordinated mandatory convertible bonds
- DGAP-News: Biofrontera AG: Biofrontera provides clinical development updates
- DGAP-News: Biofrontera AG: European Medicines Agency recommends indication expansion of Ameluz(R) for treatment of actinic keratoses on the extremities and trunk/neck
- DGAP-News: Biofrontera AG:
- DGAP-News: Biofrontera AG: Biofrontera announces 1-year follow-up results for its phase III study of photodynamic therapy for actinic keratosis on the extremities and trunk/neck
- DGAP-Adhoc: Biofrontera AG: Biofrontera announces preliminary sales figures for the full year 2019, record sales in the 4th quarter
- DGAP-News: Biofrontera AG: Biofrontera strengthens commercial focus with reorganization of its US business
- DGAP-News: Biofrontera AG: Extraordinary General Meeting of Biofrontera AG: Biofrontera Management Board supported by large majority
- DGAP-News: Biofrontera AG: Christopher Pearson appointed new Chief Commercial Officer at US subsidiary Biofrontera Inc.
- DGAP-News: Biofrontera AG: Biofrontera to Participate in Upcoming Investor Conferences
- DGAP-Adhoc: Biofrontera AG: Biofrontera Reports Third Quarter 2019 Financial Results and Revises Guidance
- DGAP-News: Biofrontera AG: Biofrontera Announces Conference Call on November 19, 2019 to Discuss Third Quarter 2019 Financial Results
- DGAP-News: Biofrontera AG: Biofrontera Receives Award at Fall Clinical Dermatology Conference 2019
- DGAP-Adhoc: Biofrontera AG: Biofrontera reports preliminary unaudited sales revenue for the first nine months of 2019
- DGAP-News: Biofrontera AG: Biofrontera to present at the Baader Investment Conference
- DGAP-News: Biofrontera AG: Biofrontera Files Label Extension for Ameluz in EU to include Treatment of Actinic Keratosis on Extremities and Trunk/Neck
- DGAP-News: Biofrontera AG:
- DGAP-News: Biofrontera AG: Biofrontera shows robust growth during first six months of 2019
- DGAP-News: Biofrontera AG: Biofrontera Announces Conference Call on August 27, 2019 to Discuss Half-year 2019 Financial Results
